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The adenomatous polyposis coli (APC) gene is considered as the true gatekeeper of colonic epithelial
proliferation: It is mutated in the majority of colorectal tumors, and mutations occur at early stages of tumor
development in mouse and man. These mutant proteins lack most of the seven 20-amino-acid repeats and all
SAMP motifs that have been associated with down-regulation of intracellular b-catenin levels. In addition,
they lack the carboxy-terminal domains that bind to DLG, EB1, and microtubulin. APC also appears to be
essential in development because homozygosity for mouse Apc mutations invariably results in early
embryonic lethality. Here, we describe the generation of a mouse model carrying a targeted mutation at codon
1638 of the mouse Apc gene, Apc1638T, resulting in a truncated Apc protein encompassing three of the seven
20 amino acid repeats and one SAMP motif, but missing all of the carboxy-terminal domains thought to be
associated with tumorigenesis. Surprisingly, homozygosity for the Apc1638T mutation is compatible with
postnatal life. However, homozygous mutant animals are characterized by growth retardation, a reduced
postnatal viability on the B6 genetic background, the absence of preputial glands, and the formation of
nipple-associated cysts. Most importantly, Apc1638T/1638T animals that survive to adulthood are tumor free.
Although the full complement of Apc1638T is sufficient for proper b-catenin signaling, dosage reductions of
the truncated protein result in increasingly severe defects in b-catenin regulation. The SAMP motif retained
in Apc1638T also appears to be important for this function as shown by analysis of the Apc1572T protein in
which its targeted deletion results in a further reduction in the ability of properly controlling b-catenin/Tcf
signaling. These results indicate that the association with DLG, EB1, and microtubulin is less critical for the
maintenance of homeostasis by APC than has been suggested previously, and that proper b-catenin regulation
by APC appears to be required for normal embryonic development and tumor suppression.
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Germ-line mutations at the adenomatous polyposis coli
(APC) gene lead to familial adenomatous polyposis
(FAP), an autosomal dominant condition characterized
by the development of hundreds to thousands of colorec-
tal adenomatous polyps in the second to third decade of
life (Groden et al. 1991; Nishisho et al. 1991). Virtually
all polyps are characterized by a somatic mutation at the
wild-type APC allele (Ichii et al. 1993; Levy et al. 1994).
Somatic APC mutations have also been observed in
>80% of sporadic adenomas and carcinomas (Miyoshi et
al. 1992; Powell et al. 1992; Smith et al. 1993). Thus,
mutation of the APC gene represents a very early event
in the multistep process of colorectal cancer progression.
FAP patients are also at increased risk for several extrain-
testinal manifestations (Talbot 1994). These include des-
moids, hepatoblastomas, osteomas, endocrine adeno-
mas, brain tumors, and cutaneous cysts. The develop-
ment of these lesions underscores the importance of
APC in maintaining homeostasis in many different tis-
sue types derived from all three embryonic lineages.
The APC gene encodes a 2843-amino-acid polypeptide
shown to participate in a number of cellular processes
ranging from cell cycle regulation, to apoptosis, cell ad-
hesion, cell migration, microtubule assembly, and cell
fate determination (Munemitsu et al. 1994; Baeg et al.
1995; Rubinfeld et al. 1995; Morin et al. 1996; Näthke et
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al. 1996). These functions are accomplished by a number
of functional domains scattered throughout the APC
protein (see also Fig. 1D). At its most amino-terminal
end, the APC protein contains a coiled-coil domain in-
volved in dimerization of the protein (Joslyn et al. 1993;
Su et al. 1993b), followed by seven Armadillo repeats of
yet unknown function (Polakis 1997). The most obvious
feature of the central domain of APC is the presence of
three 15-amino-acid repeats followed by a 20-amino-acid
motif repeated seven times. These repeats have been
shown to bind to and down-regulate b-catenin, respec-
tively (Rubinfeld et al. 1993; Su et al. 1993a; Munemitsu
et al. 1995). b-Catenin is well known not only for its
function in regulating cell–cell adhesion by binding to
cadherins, but also for its role as a signaling molecule in
the Wnt signal transduction pathway (for review, see
Willert and Nusse 1998). b-Catenin associates with
members of the lymphoid enhancer factor/T-cell factor
(LEF/TCF) family of transcriptional activators and
thereby modulates the transcription of Wnt target genes
(Behrens et al. 1996; Molenaar et al. 1996; Korinek et al.
1997; Morin et al. 1997). In the absence of a Wnt signal,
APC, on phosphorylation by glycogen synthase kinase
3b (GSK3b), promotes the down-regulation of b-catenin,
thereby preventing its signaling activity (Rubinfeld et al.
1996). Recently, two additional proteins, conductin and
axin, have also been implicated in the regulation of
b-catenin. Beside associating with b-catenin and GSK3b,
they interact with APC polypeptides containing a Ser-
Ala-Met-Pro (SAMP) motif present three times in its cen-
tral domain (Behrens et al. 1998; Hart et al. 1998; Naka-
mura et al. 1998). The carboxyl terminus of APC has
been shown to bind to several proteins including ho-
mologs of the Drosophila discs large tumor suppressor
protein (DLG), EB1-like proteins, microtubulin, and pos-
sibly to p34cdc2 (Munemitsu et al. 1994; Smith et al.
1994; Su et al. 1995; Matsumine et al. 1996; Makino et
al. 1997; Polakis 1997; Renner et al. 1997; Trzepacz et al.
1997).
The vast majority of both germ-line and somatic mu-
tations at the APC gene are clustered in the 58 half and
predict the truncation of the protein product (Miyoshi et
al. 1992; Nagase and Nakamura 1993). These truncated
proteins have been observed by Western analysis of lym-
phoblastoid and colorectal cancer cell lines carrying
chain-terminating mutations up to codon 1577 (Smith et
al. 1993; Gismondi et al. 1998). Mutations beyond codon
1600 are rare, and appear to result in undetectable levels
of the corresponding truncated polypeptides (Eccles et al.
1996; van der Luijt et al. 1996). Therefore, the mutation
spectrum observed at the APC gene suggests that the
carboxy-terminal domains and part of the b-catenin
regulatory domains are critical for its tumor-suppressing
function. However, the precise function of the carboxy-
terminal domains in relation to homeostasis and tumori-
genesis is still poorly understood.
Several mouse models have been generated by intro-
ducing specific mutations into the murine Apc gene. A
severe intestinal phenotype characterized by the devel-
opment of >100 intestinal tumors is observed in mice
heterozygous for the Min (multiple intestinal neoplasia)
and ApcD716 mutations (Moser et al. 1990; Su et al. 1992;
Oshima et al. 1995). Mice heterozygous for the Apc1638N
mutation are characterized by a milder intestinal tumor
phenotype (5–6 tumors per animal) in addition to a broad
spectrum of extraintestinal manifestations including
desmoids and cutaneous cysts (Fodde et al. 1994; Smits
et al. 1998). Whereas the ApcD716 and Min alleles result
in stable truncated proteins of 716 and 850 amino acids,
respectively, the Apc1638N mutation results in residual
amounts of a 182-kD truncated protein not detectable by
conventional Western analysis (M. Kielman, R. Smits, C.
Breukel, W. Edelmann, R. Kucherlapati, and R. Fodde, in
prep.).
Homozygosity for the above Apc mutations invariably
results in embryonic lethality before day 8 of gestation,
suggesting an essential role for Apc during development
(Fodde et al. 1994; Moser et al. 1995; Oshima et al. 1995).
Here we report the generation and phenotypic analysis
of the Apc1638T mouse model characterized by a stable
182-kD truncated protein comprising the amino-termi-
nal 1638 amino acids of Apc. In sharp contrast with the
above Apc mouse models, homozygosity for the
Apc1638T mutation is compatible with postnatal life.
Surprisingly, heterozygous as well as homozygous
Apc1638T animals are tumor free. Therefore, the
Apc1638T model delineates critical regions of the Apc
protein involved in tumorigenesis and development, in-
dicating that most of the carboxy-terminal domains of
Apc are less essential for its function in homeostasis
than has been suggested previously.
Results
Generation of the Apc1638T mouse model
We introduced a specific Apc chain-terminating muta-
tion into the mouse germ line by gene targeting in ES
cells. The targeting vector contained a 10.6-kb genomic
SphI fragment encompassing exon 15 of the mouse Apc
gene. A PGK–hygromycin cassette was inserted in the
same transcriptional orientation as Apc into a unique
SmaI site corresponding to codon 1638 of the endog-
enous gene (Fig. 1A). In total, 113 hygromycin-resistant
ES cell clones were screened by Southern analysis with a
3.0-kb fragment encompassing the 58 half of exon 15.
Seven clones showed the 5.5-kb BglII and 5.7-kb HindIII
fragments indicative of the correct targeting event (Fig.
1B, lane 2). Western analysis showed that this mutation
results in a stable truncated protein of 182 kD (Fig. 1C,
lane 2). Therefore, we will hereafter refer to this muta-
tion as Apc1638T (T for truncated). The truncated pro-
tein lacks the carboxy-terminal domains that bind to tu-
bulin, DLG, EB1-like proteins, and possibly p34cdc2. In
addition, only three of the seven 20-amino-acid
b-catenin down-regulating repeats and one of the three
conductin/axin-binding motifs are retained in the trun-
cated protein (Fig. 1D). Successfully targeted Apc+/1638T
ES cells were used to generate Ola129xB6 mice hetero-
zygous for the Apc1638T mutation.
Smits et al.
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Generation of Apc1638T/1638T, Apc1638N/1638T,
and Apc1638N/1638N ES cells
We have described previously the generation of the
Apc1638N mouse model and the broad tumor phenotype
associated with this mutation (Fodde et al. 1994; Smits
et al. 1998). The PGK–neomycin selectable marker used
for the generation of the Apc1638N mutation was in-
serted at the same codon 1638 of the endogenous mouse
Apc gene but in the transcriptional orientation opposite
to that of Apc. Western blot analysis of the targeted ES
cells and of several tissues derived from Apc+/1638N mice
failed to demonstrate the predicted truncated protein
(Fodde et al. 1994). This result is in contrast with the
Apc1638T mutation, in which the insertion of the hy-
gromycin gene in the same transcriptional orientation as
Apc results in the stable expression of the 182-kD trun-
cated protein. The main differences between the two tar-
geting constructs used are the type of selectable marker
and the transcriptional orientation of the marker relative
to that of the Apc gene. Subsequent investigations con-
ducted to differentiate between these two possibilities
revealed that the presence of the truncated protein was
dependent solely on the transcriptional orientation of
the selection cassette used. Only when either the PGK–
neomycin or the PGK–hygromycin gene is inserted in
the same transcriptional orientation as Apc is the trun-
cated Apc protein detectable. On the other hand, when
either selectable marker is inserted in a transcriptional
orientation opposite to that of Apc no truncated protein
is detectable by Western analysis (Fodde et al. 1996). Pre-
sumably, the latter orientation results in the generation
of antisense RNA by the selectable marker complemen-
tary to the targeted Apc1638N transcript. By using two
successive rounds of targeting with both markers in ei-
ther the antisense or the sense transcriptional orienta-
tion as Apc or a combination of both orientations, we
successfully obtained Apc1638T/1638T, Apc1638N/1638T,
and Apc1638N/1638N ES cells (Fig. 1C, lanes 3–5).
Mice homozygous for the Apc1638T mutation
are viable
Surprisingly, when Ola129xB6 mice heterozygous for the
Apc1638T mutation were intercrossed, homozygous
Figure 1. (A) Generation of the Apc1638T mutation. Sche-
matic drawing of exon 15 of the mouse Apc gene, the targeting
vector, and the resulting mutant allele. The PGK–hygromycin
cassette was inserted at the SmaI site corresponding to codon
1638. Some of the restriction sites used for cloning or South-
ern analysis are shown. For the generation of the Apc1572T
mutation, the PGK–hygromycin cassette was inserted be-
tween the same SmaI site and the SspI site corresponding to
codon 1572. (B) Southern blot analysis of BglII and HindIII-
digested DNA isolated from the various Apc-targeted ES
clones, hybridized with a 3-kb fragment encompassing the 58
half of exon 15. Molecular sizes of wild-type and mutant frag-
ments are depicted. (Lane 1) Apc+/+; (lane 2) Apc+/1638T; (lane
3) Apc+/1572T; (lane 4) Apc1638N/1572T. (C) Western blot analy-
sis of the various Apc-targeted ES clones. Molecular sizes
of wild-type and mutant fragments are depicted. (Lane 1)
Apc+/+; (lane 2) Apc+/1638T; (lane 3) Apc1638T/1638T; (lane 4)
Apc1638N/1638T; (lane 5) Apc1638N/1638N; (lane 6) Apc+/1572T; (lane 7) Apc1638N/1572T. (D) Schematic representation of the 2843-amino-
acid full-length Apc and the truncated 1638 and 1572-amino-acid polypeptides. The Apc1638T polypeptide lacks the carboxy-terminal
domains that bind to tubulin, DLG, EB1-like proteins, and possibly p34cdc2. In addition, four of seven b-catenin down-regulating
repeats and two of three conductin/axin-binding motifs are absent. The Apc1572T polypeptide also lacks the last remaining conduc-
tin/axin-binding motif.
Apc amino-terminal half responsible for tumor suppression
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mice were obtained at the expected Mendelian frequen-
cies (21 Apc+/+, 52 Apc+/1638T, 20 Apc1638T/1638T). As all
Apc mouse models to date are characterized by an early
embryonic lethality of homozygous mutant animals, the
Apc1638T mutation represents the first example of an
Apc truncated protein that retains the essential func-
tions necessary for normal embryonic development.
To validate the correct expression of the 182-kD trun-
cated protein, Western blot analyses were performed on
protein lysates derived from brain, liver, and duodenum
of all genotypes. A polyclonal antibody raised against
amino acids 8–312 of the APC protein (AFPN) detected
both the full-length 312-kD and the truncated 182-kD
proteins as expected. Probing of the same lysates with an
affinity-purified polyclonal antibody raised against
amino acids 2260–2843 (AFPC3), revealed the wild-type
Apc protein in tissues derived from Apc+/+ and Apc+/
1638T, whereas no protein band was detected in lysates of
Apc1638T/1638T mice (Fig. 2A).
Immunoprecipitation analysis performed with AFPN
and AFPC3 on Apc+/+, Apc+/1638T, and Apc1638T/1638T ES
cell lines confirmed the results obtained by Western
analysis of the tissue lysates (Fig. 2B). Because the
Apc1638T protein can still dimerize with full-length
Apc, it is coprecipitated in Apc+/1638T cells by the
AFPC3 antibody (Fig. 2B, lane 2). Probing both the AFPN
and AFPC3 immunoprecipitates with AFPC3 again re-
vealed only the full-length Apc protein in Apc+/+ and
Apc+/1638T ES cells, whereas no additional band was de-
tected in homozygous mutant cells (result not shown).
Therefore, we conclude that the Apc1638T targeted mu-
tation encodes a 182-kD truncated protein encompassing
amino acids 1–1638 of wild-type Apc and that the car-
boxy-terminal third of the full-length protein is not ex-
pressed in Apc1638T/1638T cellular lysates.
Apc1638T and b-catenin regulation
One of the most important functional aspects of Apc is
its interaction with b-catenin. The Apc1638T protein
still contains all three 15-amino-acid b-catenin binding
repeats, three of seven 20-amino-acid b-catenin down-
regulating repeats and one of the three conductin/axin-
binding motifs. As shown in Figure 2C, b-catenin was
coprecipitated with the truncated protein. Moreover,
staining of Apc+/+ and Apc1638T/1638T mouse embryonic
fibroblasts (MEFs) and ES cells with a b-catenin mono-
clonal antibody revealed no significant differences in
b-catenin levels or subcellular distribution (data not
shown).
To investigate whether Apc1638T is still capable of
regulating b-catenin/Tcf signaling, transient transfec-
tions were performed with a luciferase reporter construct
under the control of either optimal (pTOPFLASH) or mu-
tant Tcf-binding motifs (pFOPFLASH). In cells in which
this controlling function of Apc is lost, b-catenin can
translocate to the nucleus and form a complex with
Tcf that specifically enhances transcription of the
pTOPFLASH reporter, while leaving the expression of
pFOPFLASH unaltered (Korinek et al. 1997). As shown
in Figure 3, no increased transcriptional activity of
the pTOPFLASH reporter was observed in MEFs of all
three genotypes. The same experiment was repeated
on Apc+/+, Apc1638T/1638T, Apc1638N/1638T, and
Apc1638N/1638N ES cells. Because the Apc1638N allele
encodes extremely low levels of the truncated 182-kD
protein, it is expected to be defective in b-catenin regu-
lation, thereby leading to enhanced signaling. Accord-
ingly, a 30-fold increase of the transcriptional activity of
pTOPFLASH over its mutant pFOPFLASH control was
observed in Apc1638N/1638N ES cells (Fig. 3). No specific
activation of the pTOPFLASH reporter was observed in
wild-type or in Apc1638T/1638T ES cells. In Apc1638N/1638T
ES cells haploinsufficient for the Apc1638T protein, a 2.4-
fold increase of pTOPFLASH activity was observed. Thus,
the Apc1638T protein appears to be sufficient in regulating
b-catenin/Tcf signaling only when expressed at wild-type
levels, but is slightly impaired in this function when ex-
pressed at half this dosage.
The Apc1638T protein differs from the observed trun-
cated proteins in FAP patients and in colorectal tumors,
in the presence of the conductin/axin-binding SAMP
motif. To investigate the contribution of this motif to
Figure 2. Protein analysis of the Apc1638T mutation. (A) Total
protein lysates derived from brains of Apc+/+ (lane 1), Apc+/1638T
(lane 2), and Apc1638T/1638T (lane 3) animals were either hybrid-
ized with AFPN (left) or AFPC3 (right). Similar results were
obtained for liver and duodenum. (B) Apc+/+, Apc+/1638T, and
Apc1638T/1638T ES cells were immunoprecipitated with either
AFPN or AFPC3, and subsequently hybridized with APC (Ab-1)
recognizing an amino-terminal epitope. In Apc+/1638T cells, im-
munoprecipitation of the full-length Apc with the AFPC3 anti-
body results in coprecipitation of the Apc1638T protein because
of dimerization through the amino-terminal end of Apc. (C) The
AFPN immunoprecipitations performed on the ES cells were
hybridized with b-catenin and DLG monoclonals, showing that
the Apc1638T protein is still capable of binding b-catenin, but
does not associate with DLG.
Smits et al.
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the b-catenin down-regulating function of Apc1638T, we
generated a novel truncated allele, Apc1572T, by ho-
mologous recombination in ES cells. In this case, the
targeting construct is identical to Apc1638T with the
exception of a 197-bp SspI–SmaI deletion encompassing
the first SAMP motif and corresponding to codon 1572
(Fig. 1A,D). In total, 24 of 169 clones showed the 5.3-kb
BglII and 5.5-kb HindIII fragments, indicative of a correct
targeting event (Fig. 1B, lane 3). Western analysis of the
latter revealed the presence of a 175-kD truncated pro-
tein in 14 of these lines (Fig. 1C, lane 6). A pool of the
Apc+/1572T ES clones was subsequently targeted with the
Apc1638N-targeting construct to obtain compound
Apc1638N/1572T ES lines, which can be used to determine
the b-catenin down-regulating activity of the novel trun-
cated Apc1572T protein. Two clones showing the cor-
rect BglII and HindIII restriction fragments and the 175-
kD truncated protein were obtained on screening of 230
G418-resistant clones (Fig. 1, B, lanes 4, and C, lane 7).
One of these clones was selected for use in the
b-catenin/Tcf reporter assay described above. An average
twofold increase of pTOPFLASH activity was observed
in the Apc1638N/1572T ES line when compared with the
Apc1638N/1638T clone, demonstrating that Apc1572T is
more severely impaired in b-catenin down-regulation
than Apc1638T. Therefore, the unique SAMP motif re-
tained in Apc1638T contributes significantly to the
down-regulation of b-catenin.
Subcellular localization of Apc-interacting proteins
As a number of interactions between Apc and other pro-
teins have been mapped to the carboxy-terminal third of
Apc downstream of codon 1638, we performed immuno-
histochemical analysis of Apc+/+ and Apc1638T/1638T
MEFs with monoclonal antibodies recognizing b-tubu-
lin, EB-1, and discslarge (DLG). This analysis revealed no
obvious differences in the subcellular distribution of the
above proteins between the two cell lines (Fig. 4). The
localization of tubulin throughout the cytoplasm and
within the cellular protrusions in which it has been
shown to colocalize with Apc (Näthke et al. 1996; Barth
et al. 1997; Morrison et al. 1997; Pollack et al. 1997) was
unaltered in Apc1638T/1638T MEFs. EB-1 was localized to
the microtubule network in a similar fashion in both cell
lines, showing that EB-1 localization is not dependent on
association with Apc, which is in agreement with previ-
ous reports (Berrueta et al. 1998; Morrison et al. 1998).
Staining for DLG showed a more intense staining at the
cytoplasmic membrane and an occasional perinuclear
staining but with no clear differences between the two
lines. Probing of the Apc+/+ Apc1638T/1638T immunopre-
cipitates of Figure 2B with DLG-specific antibodies con-
firmed the expected inability of Apc1638T binding to
DLG (Fig. 2C). A similar experiment with a commer-
cially available antibody raised against EB1 was incon-
clusive as no interaction with EB1 was detected in either
cell line. Similarly, attempts to localize the endogenous
levels of Apc1638T protein with various amino-terminal
antibodies were not successful.
Nuclear localization of the Apc1638T protein
It has been shown that the full-length APC protein can
localize to the nucleus. Two putative nuclear localiza-
tion signals present at amino acids 1773 and 2054 were
originally implicated for this nuclear transport (Neufeld
and White 1997). However, mutant APC proteins ex-
pressed in SW480 and HT29 that do not encompass these
nuclear localization signals, have also been detected in
the nucleus (Efstathiou et al. 1998; K. Neufeld, pers.
comm.). The subcellular localization of the Apc1638T
protein was investigated by cell fractionation of homo-
zygous mutant MEFs. As shown in Figure 5, the mutant
protein was detectable in the nuclear as well as the
Figure 3. b-Catenin/Tcf reporter assays performed in MEFs
and ES cells of the depicted genotypes. Approximately 1 × 105
MEFs or 1 × 106 undifferentiated ES cells were transfected with
either 0.75 µg of pTOPFLASH (shaded bars) or pFOPFLASH
(solid bars) luciferase reporter construct, and cotransfected with
0.75 µg of CMV-galactosidase serving as an internal control (Ko-
rinek et al. 1997). All assays were performed as triplicate trans-
fections as shown. pTOPFLASH/PFOPFLASH ratios are de-
picted for each cell line. ES cells homozygous for the Apc1638N
mutation are clearly defective in b-catenin regulation, as dem-
onstrated by an average 30-fold increase of the transcriptional
activity of pTOPFLASH over its mutant pFOPFLASH control.
In contrast, the Apc1638T protein appears to be functional both
in MEFs and ES cells when expressed at wild-type levels. In
Apc1638N/1638T ES cells haploinsufficient for the Apc1638T pro-
tein, a twofold increase of pTOPFLASH activity was observed.
Apc1572T is more severly impaired in b-catenin down-regula-
tion than Apc1638T, as demonstrated by an average twofold
increase of pTOPFLASH activity in the Apc1638N/1572T ES line
when compared with the Apc1638N/1638T clone.
Apc amino-terminal half responsible for tumor suppression
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membrane/cytoskeletal fraction, but not in the cytoplas-
mic sample. This observation represents further evi-
dence that the two putative nuclear localization signals
present at amino acids 1773 and 2054 are not essential
for translocation of APC to the nucleus.
Apc1638T mice are tumor free
The most consistent feature of all Apc mouse models
described to date is a fully penetrant predisposition to
intestinal tumors. The tumor susceptibility of
Apc1638T was investigated in 25 Apc1638T/1638T, 22
Apc+/1638T, and 25 Apc+/+ littermates of mixed Ola129/
B6 genetic background, with all mice being older than 12
months and with equal contribution of both sexes. Mean
age of analysis of all three genotypes was between 15 and
17 months of age. In addition, 21 Apc+/1638T animals
were investigated on a B6 genetic background (N9–N12)
between 9 and 12.5 months of age with a mean age of
analysis of 10.5 months. Animals were subjected to a
complete gross necroscopy with special attention to le-
sions of the intestinal mucosa. Gross lesions were
sampled and examined microscopically. Only 4 of 25 ho-
mozygous mutant animals had developed a single tumor
diagnosed as an osteosarcoma, a follicular center-cell
lymphoma, and a hepatocellular adenoma and carci-
noma, respectively. Of the 22 Ola129/B6-Apc+/1638T ani-
mals, 3 mice showed a single tumor diagnosed as a fol-
licular center cell lymphoma, a broncho-alveolar carci-
noma and a hepatocellular adenoma. In addition, a single
intestinal adenoma and follicular center cell lymphoma
were observed in a 29-month-old heterozygous female.
In the 25 wild-type control animals, similar tumor num-
bers and types were observed. These included two follic-
ular center-cell lymphomas, a hepatocellular adenoma,
and a squamous cell papilloma of the lip. Of the 21 B6-
Apc+/1638T animals, a single female of 12.5 months of age
had developed two 1.5-mm intestinal adenomas,
whereas no abnormalities were observed in the other
animals. Both the number and type of lesions observed in
the Apc1638T animals do not differ significantly from
those expected in aging mice (Zurcher et al. 1982; Smith
et al. 1973). Therefore, these results indicate that the
Apc1638T mutation does not confer a significantly in-
creased predisposition to tumor development.
Absence of preputial glands in Apc1638T/1638T animals
Although Apc1638T mice are not characterized by an
Figure 4. Immunolocalization of b-tubulin, EB-1, and
DLG in Apc+/+ and Apc1638T/1638T MEFs. Nuclei are
counterstained with DAPI. Original magnification,
630x.
Figure 5. The Apc1638T protein localizes to both membrane/
cytoskeletal and nuclear cell fractions in Apc1638T/1638T MEFs.
Following lysis and fractionation, equal amounts of total pro-
tein from the different fractions were analyzed by SDS-PAGE
and immunoblotting with APC (Ab-1) antibody. The Apc1638T
protein is present in the total sample (T), the membrane/cyto-
skeleton (M), and the nucleus (N) but not in the cytoplasm (C).
Smits et al.
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increased tumor susceptibility, homozygous mutant ani-
mals are affected by a limited number of developmental
abnormalities. During a detailed search for pathological
changes, it was noted that, in all Apc1638T/1638T males
studied, the preputial glands were absent. These acces-
sory-modified sebaceous glands are located between the
skin and the abdominal muscles on either side of the
genital bulb. Their function consists mainly in the pro-
duction of sebum used in marking and sexual behavior.
These glands arise at day 14 of gestation near the prepu-
tial fold as two primary epithelial down-growths into the
dermis, thereby giving rise to a hair follicle. Next, the
epithelial down-growth forms other secondary out-
growths. At first, no difference is apparent between the
anlagen of both sexes. Later on, the male gland develops
faster under the influence of testosterone. Postnatally,
the female secondary outgrowth remains small and de-
velops into the clitoral gland, whereas the male counter-
part differentiates into the larger preputial gland (Cunha
1975). To our knowledge, three mouse models have been
described with developmental abnormalities of the pre-
putial gland, namely the X-linked Tabby (Ta) and tes-
ticular feminization (Tfm) mutations (Drews 1975), and
a Hoxd13 (Spdh) mutant (Johnson et al. 1998). In Spdh
mice of both sexes and in Ta males, the preputial gland
anlage is completely absent, whereas in Tfm males, the
glands are formed but are unable to respond to testoster-
one and therefore remain rudimentary as in the female.
Serial transversal sections were obtained from the
lower portion of Apc1638T/1638T male and female em-
bryos at 18.5 days of gestation, and from their wild-type
littermates. As shown in Figure 6, a preputial gland an-
lagen is clearly present near the genital tubercle in the
wild-type mice, whereas it is completely absent in the
homozygous mutant mice. This observation suggests
that, as in Ta and Spdh, the initial primary downgrowth
is not formed in Apc1638T mutant mice or cannot be
distinguished from the normally occurring primitive
hair follicles. However, other characteristic features of
Ta, such as the hair growth abnormalities and the ab-
sence of sweat glands in the footpads, or the malforma-
tions of the feet in Spdh mice, are not observed in
Apc1638T (data not shown).
Nipple-associated cutaneous cysts in Apc1638T
mutant animals
The vast majority of Apc1638T/1638T males develops one
to three cutaneous cysts ranging in size from 1 to 3 mm,
which become more prominent in older animals. This
phenotypic abnormality is less clear among females in
which a cyst smaller than 1 mm has been observed only
twice among 11 Apc1638T/1638T females older than 1
year. These cysts were not present in wild-type or het-
erozygous animals, with the exception of a single 0.5-
mm cyst detected in a heterozygous female (n = 12). A
remarkable and invariant feature of the Apc1638T cysts
is that they are always present as a solitary structure in
the proximity of a nipple. No cysts were observed in
other parts of the skin, as it has been described for the
Apc1638N mouse model (Smits et al. 1998). They repre-
sent hair follicle-related lesions, histologically defined as
hybrid infundibular/matrical cysts lined by orthokera-
tinizing squamous epithelium and stretches of matrix
cells, although the infundibular differentiation was pre-
dominant. In two cases, a connection with the skin sur-
face was evident, a type of cyst often referred to as a
dilated pore (Fig. 7). The histological analysis shows that
all Apc1638T cysts appear to originate from the pilose-
baceous unit, as it has been concluded for the Apc1638N
model.
Postnatal growth retardation of homozygous
Apc1638T animals
One of the most apparent developmental abnormalities
of homozygous mutant Apc1638T animals is a postnatal
growth retardation. Litters generated by matings of
Apc+/1638T heterozygotes of mixed Ola129/B6 back-
grounds were weighed on a weekly basis from ∼10 days
of age up to 8 weeks. In total, 154 mice were analyzed: 31
Apc+/+ (9 males, 22 females), 88 Apc+/1638T (46 males, 42
females), and 35 Apc1638T/1638T (18 males, 17 females). A
Figure 6. Hematoxylin and eosin-stained cross sections of the
genital tubercle of a 18.5-day-old wild-type male embryo (A) and
a homozygous Apc1638T male littermate (B). Two preputial
gland anlagen (arrow) are clearly present in the mesenchyme
adjacent to the urethra (UT) of the wild-type embryo, whereas
they are completely absent at the corresponding position in the
homozygous mutant embryo. In both embryos, primitive hair
follicles (arrowheads) have formed with no apparent histological
difference (Bar, 250 µm).
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significant 20% growth retardation was already apparent
in homozygous mutant animals of both sexes at 10 days
of age (P = 0.001). This growth retardation became more
pronounced in older mice. In contrast, heterozygous
mice have body weights similar to those of wild-type
mice. A growth curve relative to mice between 2 and 8
weeks of age of all three genotypes is shown in Figure 8.
To investigate whether the growth retardation of ho-
mozygous mutant animals is already present in utero,
B6-Apc+/1638T animals were bred and the litters analyzed
at 18.5 days of gestation. In total, 46 embryos derived
from 6 litters were analyzed, 10 of which were Apc+/+, 23
Apc+/1638T, and 13 Apc1638T/1638T, with equal distribu-
tion of both sexes. The average weight was not signifi-
cantly different among the three genotypes (+/+ 1.15
gram; +/− 1.11 gram; −/− 1.07 gram; P = 0.22). As ob-
served with the mixed Ola129/B6 genetic background,
B6-Apc1638T/1638T animals that survive to adulthood (see
below) are clearly smaller than their heterozygous and
wild-type littermates. Therefore, the growth retardation
of Apc1638T/1638T animals becomes apparent postnatally.
Genetic background-dependent postnatal mortality of
Apc1638T/1638T mice
As described above, intercrosses of heterozygous animals
of mixed Ola129/B6 background resulted in the expected
numbers of homozygous mutant mice at weaning. How-
ever, when the Apc1638T mutation was backcrossed to
B6, it became apparent that with increasing genetic con-
tribution of this inbred strain, a relative lower number of
mutant animals survived to adulthood. Of a total of 17
litters derived from intercrosses of N5–N12 backcross
generations, only 5 homozygous mutant animals were
alive at weaning, compared with 63 heterozygous and 26
wild-type mice. Analysis of 1-day-old litters from B6-
Apc+/1638T intercrosses revealed that 12 of 20 suc-
cumbed newborns were of the Apc1638T/1638T genotype.
This result strongly suggests that homozygosity for the
Apc1638T mutation on the B6 genetic background re-
sults in a reduced postnatal viability. With the exception
of the macroscopic absence of milk in the stomachs of all
succumbed animals, no other gross abnormalities were
observed. Microscopic examination of five nonautolytic
dead newborns and of seven 18.5 dpc embryos did not
reveal any lesions or malformations that could explain
the high postnatal mortality.
Discussion
The large number of APC mutations identified to date in
FAP patients and in colorectal tumors denote a critical
region that has to be deleted to trigger the tumorigenic
process. In fact, the majority of the above mutations lead
to the truncation of the APC protein upstream of the
conductin/axin-binding SAMP motifs (Smith et al. 1993;
Gismondi et al. 1998). On the basis of these observa-
tions, several investigators have concluded that the car-
boxy-terminal third of APC encompasses important tu-
mor-suppressing functional domains. Of the few muta-
Figure 7. Histological appearance of a cutaneous cyst observed
in a Apc1638T/1638T female. In this case, the predominantly in-
fundibular epithelium of the cyst is in open connection with the
skin surface. All Apc1638T cysts were present in the proximity
of a nipple. Accordingly, some mammary ducts (MD) can be
observed in the near vicinity of this cyst. Most of the other
Apc1638T cysts were located deep in the dermis or in the sub-
cutaneous fat layer above the panniculus carnosus, as it has
been described for the Apc1638N mouse model (Smits et al.
1998). Section was stained with hematoxylin and eosin (Bar, 320
µm).
Figure 8. Growth curve of 35 Apc1638T/1638T mice (j) and their
wild-type, (31, h) and heterozygous (88, d) littermates. All mice
were weighed on a weekly basis between 10 days and 8 weeks of
age. Standard deviations are indicated as vertical bars. The av-
erage weights shown for each time point and genotype represent
averages from both sexes. However, similar curves are obtained
if the data are analyzed for each sex separately. Therefore, both
male and female Apc1638T/1638T animals are characterized by a
growth retardation.
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tions located beyond the most amino-terminal SAMP
motif, the ones that have been studied by Western analy-
sis were shown not to result in the predicted truncated
polypeptides (Eccles et al. 1996; van der Luijt et al. 1996).
Regulation of intracellular b-catenin levels is thought
to represent one of the most important functions of the
APC tumor suppressor protein. Three different motifs in
the central domain of APC are responsible for this activ-
ity (Fig. 1D). The three 15-amino-acid repeats bind
b-catenin, whereas the seven 20-amino-acid repeats both
bind and down-regulate b-catenin. More recently, APC
polypeptides containing only one of the three SAMP mo-
tifs present in the central portion of the full-length pro-
tein have been shown to bind to conductin and axin.
Although the physical interaction of the SAMP motif
has only been formally proven for conductin, on the ba-
sis of sequence homology, it is most likely that axin
might also bind in a similar fashion. Both conductin and
axin can form a multiprotein complex with APC,
GSK3b, and b-catenin, thereby promoting the down-
regulation of the latter (Behrens et al. 1998; Hart et al.
1998; Nakamura et al. 1998). The Apc1638T truncated
protein encompasses three of the seven b-catenin down-
regulating repeats and one of the three conductin/axin-
binding SAMP motifs. As shown in Figure 3, regulation
of intracellular b-catenin appears to be normal in
Apc1638T/1638T ES cells and MEFs. Accordingly, hetero-
zygous as well as homozygous mice do not show an in-
creased tumor predisposition when compared with wild-
type animals. However, increasingly reduced dosages of
the same Apc1638T protein in Apc1638N/1638T and
Apc1638N/1638N ES cells result in a 2- and 30-fold increase
of pTOPFLASH activity when compared with its
Apc1638T/1638T full complement. The targeted deletion
of the remaining conductin/axin binding motif results in
a further increase in pTOPFLASH activity. In this regard,
it is interesting to note that germ-line APC mutations
resulting in truncated proteins encompassing three 20-
amino-acid repeats do lead to familial polyposis (Nagase
et al. 1993; Gismondi et al. 1997). The latter truncated
polypeptides, however, do not include any of the SAMP
motifs. This suggests that under physiological circum-
stances, the multiprotein complex of APC, conductin/
axin, GSK3b, and b-catenin is necessary for the accurate
regulation of intracellular b-catenin levels and that this
regulatory activity represents the main tumor suppress-
ing function of APC.
The tumor-free phenotype of Apc1638T mice also in-
dicates that deletion of the carboxy-terminal domains
that bind to tubulin, DLG, and EB-1 does not directly
predispose to tumor development. A number of investi-
gations have focused on the putative role of APC in me-
diating microtubular-associated processes that are im-
portant for proper cell division and migration. APC frag-
ments containing the microtubule-binding site can
induce assembly and bundling of microtubules in vitro
(Smith et al. 1994; Munemitsu et al. 1994), in which
process EB-1 has also been implicated (Beinhauer et al.
1997; Muhua et al. 1998). Moreover, APC has been
shown to cluster in cellular protrusions involved in ac-
tive cell migration, a localization that was dependent on
an intact microtubule cytoskeleton (Näthke et al. 1996;
Barth et al. 1997; Morrison et al. 1997; Pollack et al.
1997). Taken together, these data are suggestive for an
important role of APC in the assembly and stabilization
of microtubules. However, the data presented here sug-
gest that this postulated function of APC is not essential
for its tumor-suppressing activity, or at least that the
association with the microtubules via its carboxy-termi-
nal domains may not be required in this respect. It re-
mains plausible that, once b-catenin regulation is suffi-
ciently impaired, deletion of the microtubule binding-
site or of any other carboxy-terminal domains
contributes to APC-driven tumorigenesis.
The early embryonic lethality of the Apc mutant
mouse models described to date strongly suggests that
Apc is required for normal embryonic development. In
the Min, ApcD716 and Apc1638N models, embryonic le-
thality occurs shortly after implantation (Fodde et al.
1994; Moser et al. 1995; Oshima et al. 1995). The severe
developmental defects of these Apc mutant mice con-
trast with the observed viability of Apc1638T homozy-
gotes. Whereas the Min and ApcD716 truncated proteins
only retain the dimerization domain and the Armadillo
repeats, Apc1638T encompasses all three 15-amino-acid
b-catenin-binding repeats, three of the seven down-regu-
lating 20-amino-acid repeats and one of three SAMP re-
peats. These motifs apparently provide sufficient
b-catenin regulation to ensure proper embryonic devel-
opment.
Nevertheless, mice homozygous for the Apc1638T
mutation are characterized by several developmental ab-
normalities such as growth retardation, a reduced post-
natal viability on the B6 genetic background, the absence
of preputial glands, and the formation of nipple-associ-
ated cysts. The causes for these abnormalities could be
twofold. They could be the consequence of either the
loss of function of the carboxy-terminal domains, or be
due to a slightly reduced ability to properly control cy-
toplasmic b-catenin levels. Although the Apc1638T pro-
tein appears to normally regulate b-catenin in ES cells if
expressed at the wild-type levels, its b-catenin down-
regulating capacity is partly affected when the dosage of
protein is reduced. Accordingly, the observation that
compound heterozygous Apc1638N/1638T mice are embry-
onic lethal (M. Kielman, R. Smits, C. Breukel, W. Edel-
mann, R. Kucherlapati, and R. Fodde, in prep.) supports
that dosage of the Apc1638T truncated protein is critical
to ensure development. In these animals, the functional
dosage of b-catenin regulation provided by Apc1638T is
reduced by ∼50%, which is presumably below the criti-
cal threshold level necessary for normal development.
Likewise, in Apc1638T homozygotes, the level of regu-
lation provided by Apc1638T is below tissue-specific
thresholds, thereby resulting in developmental distur-
bances in a subset of cell types. In the case of the prepu-
tial gland that initially arises as other hair follicles,
Apc1638T-driven b-catenin regulation may be insuffi-
cient to distinguish it from other hair follicles. It should
be noted that the cutaneous cysts of both Apc1638T ho-
Apc amino-terminal half responsible for tumor suppression
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mozygotes as well as Apc1638N heterozygotes are also
associated with abnormal hair follicle development
(Smits et al. 1998), suggesting that this structure is sen-
sitive to proper regulation by Apc.
A possible explanation for both the growth retardation
and the reduced postnatal viability on the B6 genetic
background might be represented by a defect in suckling
behavior. Accordingly, milk was never found in the
stomach of the succumbed newborns and growth retar-
dation becomes apparent only after birth when compe-
tition for food may have a dramatic effect on growth. The
APC protein is also expressed at high levels in the brain
(Bhat et al. 1994; Senda et al. 1998), and it has been
shown to bind and colocalize with DLG in a multipro-
tein complex at synapses of cultured hippocampal neu-
rons (Matsumine et al. 1996; Satoh et al. 1997). These
complexes are thought to have a function in the molecu-
lar organization of synapses and neuronal cell signaling.
Because the Apc1638T protein can no longer associate
with DLG, its absence in these complexes may result in
a reduced functionality of the central nervous system
and possibly result in behavioral abnormalities.
In conclusion, the absence of a tumor phenotype and
of major developmental abnormalities in Apc1638T in-
dicates that this mutant protein harbors the majority of
the domains required for its normal function. Hence, the
regulation of cytoplasmic b-catenin levels by APC must
be sufficiently impaired to successfully lead to tumor
formation.
Materials and methods
Generation of Apc mutant embryonic stem cells and mice
Four targeting vectors were constructed by inserting a PGK–
neomycin or PGK–hygromycin cassette in both possible orien-
tations into a unique SmaI site within a 10.6-kb genomic SphI
fragment. This SmaI site corresponds to codon 1638 of the Apc
coding sequence. For the generation of the Apc1572T mutation,
PGK–hygromycin was inserted in between the unique SmaI site
and a SspI site corresponding to codon 1572, obtained after par-
tial digestion of the 10.6-kb SphI fragment. The hygromycin
cassette was inserted in the same transcriptional orientation as
that of Apc. For all targeting vectors, the introduction of the
selectable marker results in a short frameshift and in few addi-
tional residues (6–27) at the carboxy terminus of the predicted
truncated Apc proteins, differing for each construct. They do
not harbor any known destabilizing motifs, possibly explaining
the absence of a truncated protein in case PGK–neomycin or
PGK–hygromycin are inserted in the transcriptional orientation
opposite to that of Apc (see Results).
Approximately 40 µg of each construct was used to transfect
2 × 107 E14 ES cells by electroporation (1000 V/cm, 250 µF).
Hygromycin or G418 selection was applied 24 hr after transfec-
tion. All candidate ES clones were validated by Southern and
Western analysis as described (Fodde et al. 1994). Double-mu-
tant ES cell lines were generated by use of an additional round
of targeting with the second available selectable marker.
Correctly modified Apc+/1638T ES clones were injected into
C57BL/6J blastocysts, after which chimeric mice with high lev-
els of ES cell contribution were backcrossed to C57BL/6JIco
females. To assess germ-line transmission of the mutation, tail
DNA was genotyped in a single PCR-reaction with the follow-
ing primers: Apc-A (58-TGCCAGCACAGAATAGGCTG-38)
and Apc-C (58-GTTGTCATCCAGGTCTGGTGTAA-38) result-
ing in a 295-bp product indicative of the wild-type allele; PN3
(58-GCCAGCTCATTCCTCCACTC-38) in combination with
Apc-C resulting in an ∼400-bp product indicative of the
Apc1638T mutation. Amplifications were performed in a 25 µl
volume containing 10 mM Tris-HCl (pH 8.9), 50 mM KCl, 2.5
mM MgCl2, 10% glycerol, 200 µg/ml BSA, 0.01% gelatin, 0.2
mM of each dNTP, 0.2 units of Taq polymerase, and 10 pmole of
each primer. The reactions were heated for 5 min at 94°C fol-
lowed by 35 PCR cycles at 94°C for 30 sec, 55°C for 60 sec, and
72°C for 90 sec.
Antibodies
The AFPN and AFPC3 polyclonal antibodies were raised in rab-
bits by injecting a His-tagged fusion protein containing amino
acids 8–312 or 2260–2843, respectively, of the human APC pro-
tein. AFPC3 was affinity-purified with the His-tagged fragment
coupled to CNBr-activated Sepharose (Pharmacia) according to
the manufacturer’s instructions. In addition, the following com-
mercially available antibodies were used: APC (Ab-1), a mono-
clonal antibody recognizing amino acids 1–29 of APC (Onco-
gene Research Products), clone TUB 2.1, a monoclonal antibody
recognizing b-tubulin (Sigma), monoclonal antibodies recogniz-
ing b-catenin (clone 14), DLG (clone 12), and EB-1 (clone 5), all
from Transduction Laboratories (Lexington, KY).
Immunoprecipitation and immunoblotting
Approximately 2 × 107 ES cells grown without feeder layers
were rinsed twice in PBS and lysed for 15 min at 4°C in 800 µl
of Triton X-100 immunoprecipitation (IP) buffer (30 mM Tris-Cl
at pH 7.4, 250 mM NaCl, 0.1% Triton X-100, 5 mM EDTA, 50
mM NaF) containing a cocktail of protease inhibitors (1 µ/ml
aprotinin, 20 µg/ml PMSF, µg/ml leupeptin 10, µg/ml pepstatin
10, 1 µg/ml antipain, and 0.1 mM sodium vanadate). To 400 µl
of a cleared lysate obtained after a 10 min centrifugation step at
11,000g, a preformed complex of antibody and protein A–Sepha-
rose beads (Pharmacia, Roosendaal, The Netherlands) was
added. After a 1 hr incubation at 4°C with continuous mixing,
the beads were washed 3–4 times with 1 ml of IP-buffer. The
pellet was resuspended in 50 µl of Laemmli sample buffer (120
mM Tris-Cl at pH 6.8, 20% glycerol, 200 mM DTT, 4% SDS,
0.02% bromophenol blue) and boiled for 5 min.
For the detection of Apc proteins by Western analysis, lysates
were resolved on SDS-agarose gels as described (Fodde et al.
1994). Lower molecular weight proteins were resolved on a 10%
SDS–polyacrylamide gel and transferred onto PVDF membranes
(Immobilon-P, Millipore) by electroblotting. The membranes
were blocked for at least 1 hr with 5% nonfat dry milk in TBST
(10 mM Tris-HCl at pH 8.0, 150 mM NaCl, 0.05% Tween 20).
After a 1-hr incubation with primary antibody, the blot was
washed 2–3 times with TBST, and subsequently incubated with
horseradish peroxidase-conjugated secondary antibodies for 1
hr. The peroxidase was visualized by enhanced chemilumines-
cence according to the manufacturer’s instructions (Amer-
sham). Antibodies were used at the following dilutions: Apc
(Ab-1) (1:2000); AFPN (1:3000); AFPC3 (1:2000); monoclonal
b-catenin (1:5000).
Immunofluorescence
For immunofluorescence analyses, Apc+/+ and Apc1638T/1638T
mouse embryonic fibroblasts were seeded on 3-aminopropyltri-
ethoxy-silane coated coverslips to reach 70% to 80% conflu-
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ency. Cells were washed twice in CB buffer (10 mM Mes at pH
6.1, 150 mM NaCl, 5 mM EGTA, 5 mM MgCl2, 5 mM glucose)
and subsequently fixed for 5 min in CB containing 3% para-
formaldehyde and 0.3% Triton X-100. After a single wash in CB,
the cells were fixed for an additional 15 min in CB containing
3% paraformaldehyde, followed by two washes in CB. For EB-1
staining, cells were washed in PBS and fixed in methanol at
−20°C for 5 min, followed by three washes in PBS. After fixa-
tion, the cells were incubated in TBS (20 mM Tris-HCl at pH 7.5,
150 mM NaCl, 2 mM EGTA, 2 mM MgCl2) containing 5% nonfat
dry milk for 30 min. Primary antibodies were incubated for 1 hr
at room temperature in TBS/5% nonfat dry milk at the follow-
ing dilutions: b-tubulin (1:200); EB-1 (1:50); DLG (1:25);
b-catenin (1:1000). After three washes in TBS containing 0.2%
Tween-20, the cells were incubated for 30 min in a 1:500 dilu-
tion of Alexa 594 goat anti-mouse IgG secondary antibody (Mo-
lecular Probes), diluted in TBS/5% nonfat dry milk containing
0.5 µg/ml DAPI for DNA counterstaining. Following three
washes in TBS containing 0.2% Tween-20, the coverslips were
mounted in Gelvatol. Stained cells were examined by a Leitz
DM-RBE microscope with a 63× objective and mounted with a
Photometrics Series 200, KAF1400 CCD camera.
b-catenin/Tcf reporter assays
Approximately 1 × 105 MEFs or 1 × 106 undifferentiated ES cells
were transfected with 0.75 µg of the luciferase reporter con-
struct pTOPFLASH or pFOPFLASH kindly provided by Dr. H.
Clevers (Korinek et al. 1997) using the Fugene lipofection re-
agent (Boehringer Mannheim). Both constructs contain a lucif-
erase gene driven by a minimal TK promotor downstream of an
optimal TCF-binding motif (pTOPFLASH) or a mutant motif
(pFOPFLASH). Cells were cotransfected with 0.75 µg of
pcDNA3.1/Myc-His/lacZ (Invitrogen) containing a b-galactosi-
dase gene under the control of a CMV promoter, serving as an
internal control. After 40 hr, the cells were lysed in cell culture
lysis reagent provided by the Luciferase Assay System (Promega)
and luciferase activity was determined on a Berthold Lumat
LB9501 scintillation counter. b-Galactosidase activity was de-
termined as described (Sambrook et al. 1989). All assays were
performed as triplicate transfections.
Cell fractionation
Cellular fractionations were performed as described previously
(Neufeld and White 1997). Following fractionation, 70 µg of
total protein from each fraction was resolved by SDS-PAGE and
transferred to nitrocellulose for Western blot analysis.
Histological processing of tissues
Tissues were fixed overnight at 4°C in Notox (Earth Safe Indus-
tries, Inc., Belle Mead, NJ) or 10% buffered formalin and em-
bedded in paraffin according to standard procedures. Sections
were stained with hematoxylin and eosin.
For the analysis of the preputial gland from 18.5-dpc C57BL/
6J (N10–N12) embryos, serial transversal sections of the lower
half of the body were made, with a maximum interval between
two successive sections of 100 µm.
Intact, nonautolytic Apc1638T/1638T mice were found dead
shortly after birth, and 18.5-dpc embryos were fixed in Notox or
10% buffered formalin, cut longitudinally in 1-mm-thick sec-
tions, paraffin embedded, and processed to hematoxifin- and
eosin-stained sections. Microscopic examination allowed
screening for lesions or malformations in most organs or tis-
sues.
Growth measurements of animals
Heterozygous animals of mixed Ola129/B6 backgrounds (N1–
N3 backcrosses to B6) were crossed to generate mice of all
Apc1638T genotypes for the growth curve determination. At
∼10 days of age, the mice were tagged, weighed, and genotyped.
Subsequent weight measurements were performed weekly up to
8 weeks of age. For growth determination of 18.5-day embryos,
heterozygous B6-Apc+/1638T animals were mated. All extraem-
bryonic tissues were removed, followed by the weight measure-
ment. Tail DNA was isolated for genotyping and sex determi-
nation. In a single PCR-reaction with the same conditions as
described for the genotyping, primers for the Y-chromosome
specific Sry gene, that is, Sry-1 (58- GAGAGCATGGAGGGC-
CAT-38) and Sry-2 (58-CCACTCCTCTGTGACACT-38) result-
ing in a 265-bp product, were combined with X-chromosomal
primers, that is, D79F1 (58-AATAAATGTTTTACAACTCCT-
GATTCC-38) and D79R4 (58-TGCATAGACGTGTAAAAC-
CTGC-38) resulting in a 194 bp-product.
To statistically evaluate the body weight data of mice 10 days
to 8 weeks of age, a two-way ANCOVA was performed with
gender and genotype as factors and littersize as covariable. A
one-way ANOVA with genotype as factor was performed to
analyze the data of the 18.5-dpc embryos.
Generation of mouse embryonic fibroblasts
Embryonic fibroblasts were isolated essentially as described by
Hogan et al. (1994). Embryos aged 14.5–16.5-dpc were obtained
from matings of Apc+/1638T animals. After removal of the inter-
nal organs, limbs, and head, followed by several washes in PBS,
embryos were minced and treated for 15 min at 37°C with 10 ml
of 0.3% trypsin/PBS. DMEM supplemented with 10% fetal calf
serum was added to inactivate the trypsin, after which the cells
were seeded onto culture dishes.
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